Article
Interaction Testing and Polygenic Risk Scoring to Estimate the Association of Common Genetic Variants With Treatment Resistance in Schizophrenia.
JAMA psychiatry - 1 Mar 2022
Pardiñas Antonio F, Smart Sophie E, Willcocks Isabella R, Holmans Peter A, Dennison Charlotte A, Lynham Amy J, Legge Sophie E, Baune Bernhard T, Bigdeli Tim B, Cairns Murray J, Corvin Aiden, Fanous Ayman H, Frank Josef, Kelly Brian, McQuillin Andrew, Melle Ingrid, Mortensen Preben B, Mowry Bryan J, Pato Carlos N, Periyasamy Sathish, Rietschel Marcella, Rujescu Dan, Simonsen Carmen, St Clair David, Tooney Paul, Wu Jing Qin, Andreassen Ole A, Kowalec Kaarina, Sullivan Patrick F, Murray Robin M, Owen Michael J, MacCabe James H, O'Donovan Michael C, Walters James T R, Ajnakina Olesya, Alameda Luis, Barnes Thomas R E, Berardi Domenico, Bonora Elena, Camporesi Sara, Cleusix Martine, Conus Philippe, Crespo-Facorro Benedicto, D'Andrea Giuseppe, Demjaha Arsime, Do Kim Q, Doody Gillian A, Eap Chin B, Ferchiou Aziz, Di Forti Marta, Guidi Lorenzo, Homman Lina, Jenni Raoul, Joyce Eileen M, Kassoumeri Laura, Khadimallah Inès, Lastrina Ornella, Muratori Roberto, Noyan Handan, O'Neill Francis A, Pignon Baptiste, Restellini Romeo, Richard Jean-Romain, Schürhoff Franck, Španiel Filip, Szöke Andrei, Tarricone Ilaria, Tortelli Andrea, Üçok Alp, Vázquez-Bourgon Javier
Abstract excerpt
IMPORTANCE: About 20% to 30% of people with schizophrenia have psychotic symptoms that do not respond adequately to first-line antipsychotic treatment. This clinical presentation, chronic and highly disabling, is known as treatment-resistant schizophrenia (TRS). The causes of treatment resistance and their relationships with causes underlying schizophrenia are largely unknown. Adequately powered genetic studies...
Topics
Join the communities discussing this publication.